Abiraterone acetate for the treatment of prostate cancer

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.1, 2013-01, pp. : 91-96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

By Wissing Michel D van Diest Paul J van der Wall Elsken Gelderblom Hans

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 5, 2013-06 ,pp. : 635-661

Informa Healthcare

Access to resources Recommend Favorite

Vemurafenib for the treatment of melanoma

By Jordan Emmet John Kelly Catherine M

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 17, 2012-12 ,pp. : 2533-2543

Informa Healthcare

Access to resources Recommend Favorite

Prostate cancer: abiraterone acetate beats cabazitaxel

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 667, 2012-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Abiraterone Acetate: In Metastatic Castration-Resistant Prostate Cancer

By Yang Lily P.H.

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2067-2077

Adis International

Access to resources Recommend Favorite

Abiraterone acetate for castration resistant prostate cancer

By Shah Shreya Ryan Charles

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 4, 2010-04 ,pp. : 563-570

Informa Healthcare

Access to resources Recommend Favorite